Tech Company Financing Transactions
Syntimmune Funding Round
On 6/22/2017, Syntimmune received $50 million in Series B funding from Apple Tree Partners and private investors.
Transaction Overview
Company Name
Announced On
6/22/2017
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series B
Investors
Apple Tree Partners (Lead Investor) (Sam Hall)
Proceeds Purpose
Funds from the Series B financing will further advance Syntimmune's clinical development program, which includes two ongoing Phase 1b/2a clinical trials of the company's lead drug candidate, SYNT001, in pemphigus and warm autoimmune hemolytic anemia.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
116 Huntington Ave. 301
Boston, MA 02116
USA
Boston, MA 02116
USA
Phone
Website
Email Address
Overview
Founded in 2013, Syntimmune is the world's leader in the biology of the neonatal Fc receptor (FcRn). Helmed by the most recognized experts in its field, Syntimmune is positioned to rapidly advance breakthrough therapies which co-opt this unique target.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jean Kress
Chief Financial Officer
John McBride
Chief Medical Officer
Mario Saltarelli
Vice President
Stephanie Haller
Vice President
Nicole Luosey
VP - Operations
Adam Hansard
VP - Regulatory Affairs
Donald Johns
VP - Regulatory Affairs
Leslie Stolz
Browse more venture capital transactions:
Prev: 6/22/2017: Celtra venture capital transaction
Next: 6/22/2017: GreatHorn venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document every notable VC transaction. VC investment data records reported here are derived from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs